Outputs (54)

Integrated care policy recommendations for complex multisystem long term conditions and long COVID (2024)
Journal Article
van der Feltz-Cornelis, C. M., Sweetman, J., Turk, F., Allsopp, G., Gabbay, M., Khunti, K., Williams, N., Montgomery, H., Heightman, M., Lip, G. Y., Crooks, M. G., Strain, W. D., Loveless, A., Hishmeh, L., Smith, N., & Banerjee, A. (2024). Integrated care policy recommendations for complex multisystem long term conditions and long COVID. Scientific reports, 14(1), Article 13634. https://doi.org/10.1038/s41598-024-64060-1

The importance of integrated care for complex, multiple long term conditions was acknowledged before the COVID pandemic but remained a challenge. The pandemic and consequent development of Long COVID required rapid adaptation of health services to ad... Read More about Integrated care policy recommendations for complex multisystem long term conditions and long COVID.

Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD (2024)
Journal Article
Monk, P. D., Brookes, J. L., Tear, V. J., Batten, T. N., Newall, C., Mankowski, M., Crooks, M. G., Singh, D., Chaudhuri, R., Leaker, B., Lunn, K., Reynolds, S., Dudley, S., Gabbay, F. J., Holgate, S. T., Djukanovic, R., & Wilkinson, T. M. (2024). Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD. Respiratory Research, 25(1), Article 228. https://doi.org/10.1186/s12931-024-02854-7

Background: Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Interferon-β is naturally produced in response to viral infection, limiting replication. This exploratory study aimed to demonst... Read More about Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.

Pathways to care for Long COVID and for long-term conditions from patients' and clinicians' perspective (2023)
Journal Article
Turk, F., Sweetman, J., Allsopp, G., Crooks, M., Cuthbertson, D. J., Gabbay, M., Hishmeh, L., Lip, G. Y., Strain, W. D., Williams, N., Wootton, D., Banerjee, A., & van der Feltz-Cornelis, C. (2023). Pathways to care for Long COVID and for long-term conditions from patients' and clinicians' perspective. Journal of Evidence-Based Medicine, 16(4), 435-437. https://doi.org/10.1111/jebm.12563

A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2 (2023)
Journal Article
Wilkinson, T., De Soyza, A., Carroll, M., Chalmers, J. D., Crooks, M. G., Griffiths, G., Shankar-Hari, M., Ho, L. P., Horsley, A., Kell, C., Lara, B., Mishra, B., Moate, R., Page, C., Pandya, H., Raw, J., Reid, F., Saralaya, D., Scott, I. C., Siddiqui, S., …on behalf of The ACCORD Collaborative Group. (2023). A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2. ERJ Open Research, 9(5), Article 00249-2023. https://doi.org/10.1183/23120541.00249-2023

Background Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving ou... Read More about A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2.

Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways) (2023)
Journal Article
Alwan, N. A., Clutterbuck, D., Pantelic, M., Hayer, J., Fisher, L., Hishmeh, L., Heightman, M., Allsopp, G., Wootton, D., Khan, A., Hastie, C., Jackson, M., Rayner, C., Brown, D., Parrett, E., Jones, G., Smith, K., Clarke, R., McFarland, S., Gabbay, M., …Cleary, N. (2023). Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways). PLoS ONE, 18(7 July), Article e0284297. https://doi.org/10.1371/journal.pone.0284297

Background and aim Long Covid is a significant public health concern with potentially negative implications for health inequalities. We know that those who are already socially disadvantaged in society are more exposed to COVID-19, experience the wor... Read More about Long Covid active case finding study protocol: A co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways).

Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site (2023)
Journal Article
Crooks, M. G., Crowther, L., Cummings, H., Cohen, J., Huang, C., Pitel, L., Pearson, M., Morice, A., Turgoose, J., Faruqi, S., Watt, M., Morris, T., & Xu, Y. (2023). Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site. ERJ Open Research, 9(3), Article 00685-2022. https://doi.org/10.1183/23120541.00685-2022

Aim: Short-acting β2-agonist (SABA) overuse adversely impacts asthma-related outcomes and the environment. The SABA rEductioN Through ImplemeNting Hull asthma guidELines (SENTINEL) programme aims to reduce SABA overuse through supported implementatio... Read More about Improving asthma care through implementation of the SENTINEL programme: findings from the pilot site.

Designing an intervention to help the quitters quit: A qualitative, intervention co-design study (2023)
Journal Article
Dyson, J., Skinner, J., Crick, J., & Crooks, M. G. (2023). Designing an intervention to help the quitters quit: A qualitative, intervention co-design study. PEC Innovation, 2, Article 100141. https://doi.org/10.1016/j.pecinn.2023.100141

Objective: E-cigarettes are increasingly being provided by publicly funded stop smoking services. Our objectives were to understand the challenges and establish the means by which services could best support the use and subsequent discontinuation of... Read More about Designing an intervention to help the quitters quit: A qualitative, intervention co-design study.

Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study (2023)
Journal Article
Killingback, C., Thompson, M., Nettleton, M., Hyde, L., Marshall, P., Shepherdson, J., Crooks, M. G., Green, A., & Simpson, A. J. (2023). Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study. Disability and Rehabilitation, https://doi.org/10.1080/09638288.2022.2159075

Purpose: The aim of this qualitative study was to explore the views of participants of a group-based, supervised, telerehabilitation programme, following discharge from hospital with Covid-19. This study was part of a single-centre, fast-track (wait-... Read More about Telerehabilitation for patients who have been hospitalised with covid-19: a qualitative study.

STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol (2023)
Journal Article
Forshaw, D., Wall, E. C., Prescott, G., Dehbi, H. M., Green, A., Attree, E., Hismeh, L., Strain, W. D., Crooks, M. G., Watkins, C., Robson, C., Banerjee, R., Lorgelly, P., Heightman, M., & Banerjee, A. (2023). STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol. PLoS ONE, 18(2), Article e0272472. https://doi.org/10.1371/journal.pone.0272472

INTRODUCTION: Long COVID (LC), the persistent symptoms ≥12 weeks following acute COVID-19, presents major threats to individual and public health across countries, affecting over 1.5 million people in the UK alone. Evidence-based interventions are ur... Read More about STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: A structured protocol.

Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study (2023)
Journal Article
Dennis, A., Cuthbertson, D. J., Wootton, D., Crooks, M., Gabbay, M., Eichert, N., Mouchti, S., Pansini, M., Roca-Fernandez, A., Thomaides-Brears, H., Kelly, M., Robson, M., Hishmeh, L., Attree, E., Heightman, M., Banerjee, R., & Banerjee, A. (2023). Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study. Journal of the Royal Society of Medicine, 116(3), 97-112. https://doi.org/10.1177/01410768231154703

Objectives: To determine the prevalence of organ impairment in long COVID patients at 6 and 12 months after initial symptoms and to explore links to clinical presentation. Design: Prospective cohort study. Participants: Individuals. Methods: In indiv... Read More about Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study.